Phospho-PTK2 (Tyr576/Tyr577) Antibody

What is PTK2 and why is phosphorylation at Tyr576/Tyr577 significant?

PTK2, also known as Focal Adhesion Kinase (FAK), is a non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation, and apoptosis . Tyr576 and Tyr577 residues are located within the activation loop of the kinase domain. Their phosphorylation is crucial for maximum catalytic activity of FAK.

Structurally, when phosphorylated, the activation loop adopts a β-hairpin-like conformation similar to that seen in other active tyrosine kinases including insulin receptor, Lck, and Jak3 . This conformation appears to be stabilized primarily by hydrogen bond and electrostatic interactions with the phosphate group of pTyr577, while the sidechain and phosphate group of pTyr576 extends into solution . This phosphorylation-induced conformational change significantly enhances FAK's kinase activity - phosphorylation of the activation loop by Src increases the activity of FAK more than twenty-fold .

What is the activation mechanism involving Tyr576/Tyr577 phosphorylation?

FAK activation follows a sequential phosphorylation cascade:

• FAK autophosphorylates at Tyr397, creating a binding site for Src family kinases

• The phosphorylated Tyr397 site and nearby "PxxP" motif recruit and activate Src via binding to its SH2 and SH3 domains

• Src then phosphorylates Tyr576 and Tyr577 in the activation loop of the FAK kinase domain

• This phosphorylation dramatically increases FAK catalytic activity

This mechanism involves releasing FAK from its autoinhibited state. In the autoinhibited conformation, the FERM domain blocks the kinase active site and prevents activation loop phosphorylation. Structural studies have shown that pTyr576 and Ala579 in the phosphorylated activation loop would collide with the FERM domain in the autoinhibited structure, suggesting that an active conformation of the activation loop and FERM domain inhibition are mutually exclusive .

What cellular functions are regulated by FAK phosphorylated at Tyr576/Tyr577?

FAK phosphorylated at Tyr576/Tyr577 regulates multiple critical cellular processes:

• Cell migration and spreading (FAK-null cells with reintroduced FAK mutants deficient in Tyr576/Tyr577 phosphorylation show decreased cell spreading and migration)

• Formation and disassembly of focal adhesions and cell protrusions

• Reorganization of the actin cytoskeleton

• Cell adhesion to components of the extracellular matrix

• Cell proliferation and apoptosis

• Signal transduction from integrins and G-protein coupled receptors

The FAK-Src signaling complex is particularly important in tumor cell behavior, suggesting that phosphorylation at these sites may provide useful indicators of increased signaling through the Src-FAK complex in tumors .

What is the optimal protocol for using Phospho-PTK2 (Tyr576/Tyr577) antibody in Western blotting?

For optimal Western blotting results with Phospho-PTK2 (Tyr576/Tyr577) antibody:

Always include samples from cells treated with Src inhibitors as negative controls, and total FAK antibody detection on parallel samples to normalize phospho-specific signals.

How can I optimize immunocytochemistry/immunofluorescence experiments with this antibody?

For successful immunocytochemistry applications:

• Fixation: Use 4% paraformaldehyde (10-15 minutes at room temperature) or methanol (10 minutes at -20°C)

• Permeabilization: Brief treatment with 0.1-0.3% Triton X-100 (5 minutes)

• Blocking: Use 1-5% BSA or serum in PBS with phosphatase inhibitors

• Antibody dilution: 1:50-1:200 range is typically effective

• Incubation time: Overnight at 4°C is recommended

• Controls: Include cells treated with FAK/Src inhibitors as negative controls

• Visualization: Secondary antibodies conjugated with fluorophores appropriate for your microscopy setup

HeLa cells are recommended as positive controls for ICC/IF applications .

How do I validate the specificity of Phospho-PTK2 (Tyr576/Tyr577) antibody?

To confirm antibody specificity:

• Phosphatase treatment: Treat one sample with lambda phosphatase to remove phosphate groups

• Peptide competition: Pre-incubate antibody with phospho-peptide immunogen to block specific binding

• Genetic validation: Use cells expressing FAK with Y576F/Y577F mutations

• Kinase inhibition: Treat cells with Src inhibitors to prevent phosphorylation at these sites

• Knockdown/knockout controls: Use FAK-null cells or siRNA knockdown samples

• Cross-validation: Compare results with another phospho-specific antibody from a different source

The antibody should detect endogenous levels of FAK only when phosphorylated at tyrosine 576/577 .

How should I interpret changes in PTK2 Tyr576/Tyr577 phosphorylation?

Proper interpretation of Phospho-PTK2 (Tyr576/Tyr577) signals requires:

• Normalization: Always normalize phospho-FAK to total FAK levels, not housekeeping proteins

• Activation state assessment: Consider these phosphorylation events as indicators of full FAK activation, occurring downstream of Tyr397 autophosphorylation

• Functional correlation: Increased phosphorylation at Tyr576/Tyr577 correlates with enhanced FAK catalytic activity (approximately 20-fold increase)

• Context dependency: Interpret phosphorylation status in the context of cell adhesion, integrin engagement, or growth factor stimulation

• Pathway analysis: Consider the activation state of upstream regulators, particularly Src family kinases

Remember that the FERM domain can block Tyr576/Tyr577 phosphorylation in the autoinhibited state, so changes in phosphorylation may reflect alterations in FAK conformation rather than just kinase activity .

What are the functional differences between Tyr576 and Tyr577 phosphorylation?

While the antibody detects both phosphorylated residues, research suggests distinct roles:

• pTyr577: The phosphate group forms stabilizing hydrogen bond and electrostatic interactions that maintain the active conformation of the activation loop

• pTyr576: The sidechain and phosphate group extend into solution, potentially serving different regulatory functions

• Conformational effects: Studies of the activated kinase domain show that the phosphorylated activation loop adopts a β-hairpin-like conformation similar to other active tyrosine kinases

• Mutual activation: Both sites contribute to maximum catalytic activity, with mutation of these residues reducing FAK activity

Advanced studies examining site-specific mutants (Y576F vs. Y577F) would be necessary to fully distinguish their individual contributions to FAK function.

How can I distinguish between direct FAK activation and compensatory phosphorylation mechanisms?

To differentiate primary activation from compensatory mechanisms:

• Time-course experiments: Primary activation events typically occur earlier than compensatory phosphorylation

• Pathway inhibition: Use selective inhibitors of upstream kinases (Src family, RET) to block direct phosphorylation

• Phosphorylation patterns: Examine multiple phosphorylation sites (Tyr397, Tyr576/577, Tyr925) to establish activation sequence

• Co-immunoprecipitation: Identify binding partners associated with different activation states

• RET-FAK transactivation: Consider that RET can directly phosphorylate FAK at Tyr576/577 (but not Tyr925), creating a reciprocal phosphorylation mechanism

Understanding the complete activation context is essential, as FAK can be activated by various stimuli including integrin clustering, antibody cross-linking, G-protein coupled receptor occupancy, and LDL receptor occupancy .

Why might I observe weak or no signal despite confirmed FAK expression?

Common causes for weak Phospho-PTK2 (Tyr576/Tyr577) antibody signals include:

• Rapid dephosphorylation: Ensure phosphatase inhibitors are fresh and used at appropriate concentrations

• Inactive state: FAK may be predominantly in its autoinhibited conformation where the FERM domain blocks these phosphorylation sites

• Upstream inactivation: Src family kinases may be inactive under your experimental conditions

• Epitope masking: Protein interactions may block antibody access to the phosphorylated epitope

• Storage degradation: Phospho-epitopes are sensitive; avoid multiple freeze-thaw cycles

• Antibody concentration: May need optimization; try 1:300-1:1000 dilutions

• Cell type variation: Different cell types exhibit varying levels of basal FAK phosphorylation

To troubleshoot, include positive controls such as cells plated on fibronectin or treated with growth factors that activate the FAK-Src pathway.

How can I minimize background or non-specific signals?

To improve signal-to-noise ratio:

• Blocking optimization: Extend blocking time (1-2 hours) using 5% BSA in TBS-T

• Antibody dilution: Test a dilution series to find optimal concentration (typically 1:1000 for WB)

• Wash stringency: Increase number and duration of washes with TBS-T

• Secondary antibody: Ensure secondary antibody is highly cross-adsorbed to minimize cross-reactivity

• Negative controls: Include samples from FAK-null cells or cells treated with FAK/Src inhibitors

• Temperature control: Perform antibody incubations at 4°C to reduce non-specific binding

• Sample quality: Use fresh lysates with complete protease and phosphatase inhibitors

For immunofluorescence, additional autofluorescence quenching steps may be necessary to improve signal clarity.

What is the best way to store and handle the antibody to maintain sensitivity?

For optimal antibody performance:

• Storage temperature: Store at -20°C for long-term preservation

• Aliquoting: Divide into small single-use aliquots to avoid repeated freeze-thaw cycles

• Buffer composition: Most preparations contain 50% glycerol and 0.02% sodium azide

• Handling: Keep cold during use; return to -20°C promptly

• Dilution: Prepare working dilutions fresh each time

• Contamination prevention: Use sterile techniques when handling the antibody

• Expiration: Check manufacturer's recommended shelf-life; typically 12 months if properly stored

Always centrifuge the vial briefly before opening to collect liquid at the bottom of the tube .

How can I use this antibody to study the relationship between FAK conformation and phosphorylation?

For sophisticated structure-function studies:

• Conformation-specific analysis: Compare phosphorylation patterns between full-length FAK and the isolated kinase domain, which lacks FERM-mediated autoinhibition

• Structural comparisons: The phosphorylated activation loop adopts a β-hairpin-like conformation that would collide with the FERM domain in the autoinhibited state

• Mutational studies: Introduce mutations at the FERM/kinase interface and measure effects on Tyr576/577 phosphorylation

• Domain interaction: The F2 lobe of the FERM domain makes extensive contact with the kinase C-lobe (649 Ų buried surface area), stabilizing the autoinhibited assembly

• Conformational dynamics: Study how release of FERM-mediated inhibition permits Src-dependent phosphorylation of the activation loop

This approach can reveal how structural changes regulate FAK activity in different cellular contexts.

What experimental approaches can differentiate the roles of Tyr576 versus Tyr577 phosphorylation?

To distinguish the specific contributions of each phosphorylation site:

• Single-site mutants: Generate Y576F and Y577F mutants for comparative functional analysis

• Site-specific phosphorylation: Use mass spectrometry to quantify individual site phosphorylation under different conditions

• Structural analysis: Compare with crystal structures showing that pTyr577 forms stabilizing interactions while pTyr576 extends into solution

• In vitro kinase assays: Assess kinase activity of variants with differential phosphorylation

• Conformational studies: Use hydrogen-deuterium exchange mass spectrometry to detect local structural changes

These approaches can reveal whether these sites have redundant or distinct roles in FAK activation and function.

How can I integrate phospho-specific antibody data with broader PTK2 signaling pathway analysis?

For comprehensive signaling pathway analysis:

• Multi-site phosphorylation profiling: Combine Tyr576/577 phosphorylation data with other FAK phosphorylation sites (Tyr397, Tyr925)

• Pathway reconstruction: Map the sequence of phosphorylation events from integrin engagement to downstream substrate phosphorylation

• Integrative approaches: Correlate FAK phosphorylation with activation of downstream effectors like paxillin and p130cas

• Cross-pathway interactions: Examine how G-protein coupled receptor activation affects FAK phosphorylation status

• Systems biology: Incorporate phospho-FAK data into computational models of adhesion signaling networks

• RET-FAK interactions: Investigate the reciprocal phosphorylation mechanism between RET and FAK where RET directly phosphorylates FAK at Tyr576/577 but not Tyr925

This integrative approach can reveal how FAK serves as a signaling node connecting multiple cellular pathways.